Provided are a series of crocins compounds and related pharmacological applications thereof in prevention and treatment of Alzheimer's disease. The series of crocins compounds are obtained by taking the Chinese herb, namely Gardenia jasminoides Ellis, as a raw material and separating same by means of various methods. The compounds playing a role in preventing oxidative injury caused by hydrogen peroxide (H.sub.2O.sub.2) and excitatory amino acid injury caused by L-glutamic acid are screened out by in-vitro cell experiments. The results show that the crocins compounds have good effect in preventing cell injury caused by H.sub.2O.sub.2 and L-glutamic acid. The compounds have good effect in preventing and treating Alzheimer's disease due to the fact that significant rise of oxidative stress and excitatory amino acid is a key factor for nerve injury in Alzheimer's disease, and have broad development and application prospect.

Active components comprising lauric acid, or a lauric acid derivative, are utilized independently, or in combination, to provide new and useful compositions for bacteriostatic action against susceptible pathogens. The lauric acid derivative includes one or more of 12-aminododecanoic acid, 12-amino-1-dodecanoic acid methyl ester, sucrose monolaurate, 12-(7-nitrobenzofurazan-4-ylamino) dodecanoic acid, 4-nitrophenyl dodecanoate, 1-lauroyl-rac-glycerol, 3-oxo-N-(2-oxocyclohexyl) dodecanamide, butyl laurate, benzyl laurate, isoamyl laurate, monolaurin, isopropyl laurate, pentyl laurate, and hexyl laurate. A preparation includes combining the active component with lecithin, and after an initial processing phase, coating with chitosan or a carrier. Final compositions may be or may contain particles, such as nanoparticles. Final compositions, or formulations containing said final compositions, may be utilized internally, causing one or more membrane changes (e.g., a membrane of an internal target pathogen, which may or may not be an antibiotic-resistant pathogen). At least some compositions inhibit growth of one or more Gram-positive bacterial species and one or more Gram-negative bacterial species.

Active components comprising lauric acid, or a lauric acid derivative, are utilized independently, or in combination, to provide new and useful compositions for bacteriostatic action against susceptible pathogens. The lauric acid derivative includes one or more of 12-aminododecanoic acid, 12-amino-1-dodecanoic acid methyl ester, sucrose monolaurate, 12-(7-nitrobenzofurazan-4-ylamino) dodecanoic acid, 4-nitrophenyl dodecanoate, 1-lauroyl-rac-glycerol, 3-oxo-N-(2-oxocyclohexyl) dodecanamide, butyl laurate, benzyl laurate, isoamyl laurate, monolaurin, isopropyl laurate, pentyl laurate, and hexyl laurate. A preparation includes combining the active component with lecithin, and after an initial processing phase, coating with chitosan or a carrier. Final compositions may be or may contain particles, such as nanoparticles. Final compositions, or formulations containing said final compositions, may be utilized internally, causing one or more membrane changes (e.g., a membrane of an internal target pathogen, which may or may not be an antibiotic-resistant pathogen). At least some compositions inhibit growth of one or more Gram-positive bacterial species and one or more Gram-negative bacterial species.

This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for delivery of agents to biological surfaces and/or the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compositions for treating disorders including diabetes type II and clinical obesity that require a modulation of certain nutrients to the body.

The present invention relates to a composition, preferably for oral use, comprising a simethicone and sucrose esters (sucrester) and, optionally, at least one food or pharmaceutical grade additive and/or excipient. Furthermore, the present invention relates to said composition for use in a method for the treatment of disorders of the gastrointestinal tract, in particular of intestinal colics, especially in paediatric subjects and in neonates, abdominal cramps, flatulence, tympanites, aerophagia, swelling of the abdomen, dyspeptic disorders (or dyspepsia) and disorders that require a reduction in gastric emptying time. Lastly, the present invention relates to the non-therapeutic use of said composition as antifoam.

The present invention relates to a composition, preferably for oral use, comprising a simethicone and sucrose esters (sucrester) and, optionally, at least one food or pharmaceutical grade additive and/or excipient. Furthermore, the present invention relates to said composition for use in a method for the treatment of disorders of the gastrointestinal tract, in particular of intestinal colics, especially in paediatric subjects and in neonates, abdominal cramps, flatulence, tympanites, aerophagia, swelling of the abdomen, dyspeptic disorders (or dyspepsia) and disorders that require a reduction in gastric emptying time. Lastly, the present invention relates to the non-therapeutic use of said composition as antifoam.

The present invention relates to a composition, preferably for oral use, comprising a simethicone and sucrose esters (sucrester) and, optionally, at least one food or pharmaceutical grade additive and/or excipient. Furthermore, the present invention relates to said composition for use in a method for the treatment of disorders of the gastrointestinal tract, in particular of intestinal colics, especially in paediatric subjects and in neonates, abdominal cramps, flatulence, tympanites, aerophagia, swelling of the abdomen, dyspeptic disorders (or dyspepsia) and disorders that require a reduction in gastric emptying time. Lastly, the present invention relates to the non-therapeutic use of said composition as antifoam.

The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier.

The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier.

The present disclosure relates to a method for treating or preventing or delaying the onset or progression of an amyloidogenic disease in a subject in need, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of amphiphilic liposaccharide to the subject. The present disclosure also relates to a method for selecting an agent for treating or preventing or delaying the onset or progression of an amyloidogenic disease and a novel liposaccharide.